D-Serine has recently been described to be present in the brain at high concentrations. However, while prior research has demonstrated that L-phosphoserine is the major precursor of L-serine in the brain, the possible role of D-phosphoserine as the direct precursor of D-serine is unknown. To address this problem, we developed an assay to separate and quantitate D- and L-phosphoserine. A very simple HPLC-UV procedure for the separation and quantification of D- and L-phosphoserine is presented using precolumn derivatization with a chiral reagent, N alpha-(2,4-dinitro-5-fluorophenyl)-L-alaninamide (Marfey's reagent), and a conventional C18 reversed-phase column. The procedure is sensitive to 11 pmol on-column and derivatives are stable for at least two weeks at room temperature. Rat brain regions (cortex, hippocampus, striatum, and cerebellum) were analyzed for the presence of D- and L-phosphoserine. It was determined that the brain regions studied contained exclusively L-phosphoserine.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0378-4347(95)00221-4 | DOI Listing |
J Chromatogr A
January 2025
Waters Corporation, Instrument/Core Research/Fundamental, Milford, MA, 01757, USA. Electronic address:
Significant progress has been made in the last two decades in producing small (<2μm), high-purity, and low-adsorption particles, columns and system hardware, for ultra-high pressure liquid chromatography (UHPLC). Simultaneously, the recent rapid expansion of cell and gene therapies for treating diseases necessitates novel analytical technologies for analyzing large (>2 kbp) plasmid double-stranded (ds) DNA (which encodes for the in vitro transcription (IVT) of single-stranded (ss) mRNA therapeutics) and dsRNAs (related to IVT production impurities) biopolymers. In this context, slalom chromatography (SC), a retention mode co-discovered in 1988, is being revitalized using the most advanced column technologies for improved determination of the critical quality attributes (CQAs) of such new therapeutics.
View Article and Find Full Text PDFAnal Bioanal Chem
January 2025
Center for Applied Geoscience, Department of Geosciences, Eberhard Karls University Tübingen, Tübingen, Germany.
Aminopolyphosphonates (APPs) are widely used as chelating agents, and their increasing release into the environment has raised concerns due to their transformation into aminomethylphosphonic acid (AMPA) and glyphosate, compounds of controversial environmental impact. This transformation highlights the urgent need for detailed studies under controlled conditions. Despite the availability of various methods for quantifying individual aminopolyphosphonates and aminomonophosphonates, a green, low-cost approach for the simultaneous quantification of APPs and their transformation products in laboratory experiments has been lacking.
View Article and Find Full Text PDFLab Chip
January 2025
Department of Biotechnology and Bioengineering, Izmir Institute of Technology, Izmir 35430, Turkiye.
Centrifugation is crucial for size and density-based sample separation, but low-volume or delicate samples suffer from loss and impurity issues during repeated spins. We introduce the "Spinochip", a novel microfluidic system utilizing centrifugal forces for efficient filling of dead-end microfluidic channels. The Spinochip enables versatile fluid manipulation with a single reservoir for both inlet and outlet functions.
View Article and Find Full Text PDFFront Bioeng Biotechnol
January 2025
Pharmaceutical Development Biologicals, TIP, Boehringer Ingelheim Pharma GmbH & Co., KG, Innovation Unit, Biberach an der Riss, Germany.
Polysorbates, in particular polysorbate (PS) 20 and 80, are the most commonly used surfactants for stabilising biotherapeutics produced by biotechnological processes. PSs are derived from ethoxylated sorbitan (a derivative of sorbitol) esterified with fatty acids of varying chain length and degree of saturation. In the past, these surfactants have been reported to have specific liabilities.
View Article and Find Full Text PDFTau exhibits change in both spatial extent and density of pathology along the Alzheimer's disease (AD) spectrum with each aspect contributing to the overall burden of pathological tau. Nevertheless, studies using Tau PET have measured either magnitude using standardized uptake value ratios (SUVRs) or extent using number of Tau+ regions. We hypothesized that combining these two dimensions into a single measure of Magnitude and eXtent, Tau-MaX, would provide improved quantification of global tau burden as well as allowing for a region-agnostic measure of global tau burden that does not require a pre-specified region of interest (ROI) or meta-ROI.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!